• 16006 Citations
  • 52 h-Index
1982 …2019
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Melanoma Medicine & Life Sciences
Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Esophageal Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Safety Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1982 2019

  • 16006 Citations
  • 52 h-Index
  • 185 Article
  • 2 Review article
  • 1 Chapter

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 othersRutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032
5 Citations

Current status and perspectives in immunotherapy for metastatic melanoma

Marconcini, R., Spagnolo, F., Stucci, L. S., Ribero, S., Marra, E., de Rosa, F. D., Picasso, V., di Guardo, L. D., Cimminiello, C., Cavalieri, S., Orgiano, L., Tanda, E., Spano, L., Falcone, A., Queirolo, P., Palmieri, G., Stanganelli, I., Mandalà, M., Quaglino, P., Botti, G. & 3 othersCaracò, C., Sileni, V. C. & di Giacomo, A. M., Jan 1 2018, In : Oncotarget. 9, 15, p. 12452-12470 19 p.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Immune System Diseases
Drug Combinations
Pharmaceutical Preparations
38 Citations

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Chiarion-Sileni, V., Dutriaux, C., de Groot, J. W. B., Yamazaki, N., Loquai, C., Moutouh-de Parseval, L. A., Pickard, M. D., Sandor, V., Robert, C. & Flaherty, K. T., Jan 1 2018, In : The Lancet Oncology.

Research output: Contribution to journalArticle

Melanoma
PLX4032
MEK162
encorafenib
Mitogen-Activated Protein Kinase Kinases
2 Citations

Esophageal Cancer Clinical Presentation: Trends in the Last 3 Decades in a Large Italian Series

Cavallin, F., Scarpa, M., Cagol, M., Alfieri, R., Ruol, A., Sileni, V. C., Ancona, E. & Castoro, C., Jan 2018, In : Annals of Surgery. 267, 1, p. 99-104 6 p.

Research output: Contribution to journalArticle

Esophageal Neoplasms
Comorbidity
Stomach Ulcer
Malnutrition
Lung Diseases
Italy
Pharmaceutical Preparations
Waste Management
Economics
ipilimumab